INOZYME PHARMA INC (INZY) Stock Income Statement
NASDAQ:INZY - Nasdaq - US45790W1080 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 105.47M | 104.03M | 75.64M | 68.68M | 56.65M | |||
| Research and Development | 84.50M | 83.23M | 54.85M | 47.85M | 37.72M | |||
| Selling, General, and Administrative Expenses | 20.98M | 20.80M | 20.80M | 20.83M | 18.93M | |||
| Operating Income | -105.47M | -104.03M | -75.64M | -68.68M | -56.65M | |||
| Interest Income/Expense | 770.00K | 2.11M | 4.50M | 1.93M | 210.00K | |||
| Other Income/Expense | -111.00K | -102.00K | -28.00K | -320.00K | -190.00K | |||
| Income Before Taxes | -106.72M | -102.02M | -71.17M | -67.06M | -56.62M | |||
| Income Tax | N/A | 0.00 | N/A | N/A | N/A | |||
| Net Income | -106.72M | -102.02M | -71.17M | -67.06M | -56.62M | |||
| EBITDA | -104.74M | -103.29M | -74.81M | -67.94M | -55.98M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.68 | -1.62 | -1.37 | -1.78 | -2.40 | |||
| Non GAAP EPS | -1.68 | -1.62 | -1.37 | -1.89 | -2.39 | |||
| Statistics | ||||||||
All data in USD